Skip to main content
. 2013 Dec 12;134(4):992–1000. doi: 10.1038/jid.2013.476

Figure 1.

Figure 1

Tofacitinib prevents graft-versus-host disease (GVHD)-like disease. (a) The curves show the percentage of starting weight in mice treated with oral administration of tofacitinib daily at 50 or 12.5 mg kg–1 BID, or with vehicle control that was started on the same day as OT-I cell transfer (5–6 mice in each group). (b) Individual clinical scores of mice 14 days after OT-I cell transfer are plotted. The bars are mean scores of each group. **P<0.01, U-test. (c–i) Clinical and histological photographs of mice treated with vehicle control (c, d), or with tofacitinib daily at 12.5 (e, f) or 50 mg kg–1 BID (g, h) 14 days after OT-I cell transfer, and those of untreated mice (i, j). OT-I cells, transgenic T cells. Bar=50 μm.